Influenza virus vaccine (Fluzone)

BIOLOGICAL2 trials

Sponsors

ID Biomedical Corporation, Quebec, Seqirus

Conditions

Influenza

Phase 3

Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over

CompletedNCT00232947

ID Biomedical Corporation, QuebecInfluenza

Start: 2005-10-31End: 2006-02-28Target: 900Updated: 2007-01-22

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

CompletedNCT00959049

SeqirusInfluenza

Start: 2009-09-30End: 2010-05-31Updated: 2017-05-16